INSYS is developing a pipeline of products intended to address unmet medical needs and the clinical shortcomings of existing commercial products.
PHOENIX, March 25, 2019 (GLOBE NEWSWIRE)
INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced the Company will present a poster of its pharmacokinetic (PK) study of its novel naloxone nasal spray versus intravenous and intramuscular injection at the College on Problems of Drug Dependence (CPDD)’s 81st Annual Scientific Meeting in San Antonio, Texas on Monday, June 17, 2019 at 8:00am Central Time.
A copy of the poster will be made available on the Company’s website following the presentation.
INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve patients’ quality of life. Using proprietary spray technology and capabilities to develop pharmaceutical cannabinoids, INSYS is developing a pipeline of products intended to address unmet medical needs and the clinical shortcomings of existing commercial products. INSYS is committed to developing medications for potentially treating anaphylaxis, epilepsy, Prader-Willi syndrome, opioid addiction and overdose, and other disease areas with a significant unmet need.NOTE: All trademarks and registered trademarks are the property of their respective owners.
This news release contains both historical information and forward-looking statements. Forward-looking statements are based on management’s current expectations and assumptions as of the date of this presentation, and actual results may differ materially from those in these forward-looking statements as a result of various factors, including many which are beyond INSYS’ control. Such factors include, but are not limited to risks regarding: the expenses, impact and potential outcomes of pending claims, litigation and other legal proceedings, including the completion of the settlement in principle with the DOJ; INSYS’ indemnification obligations for former executives; the heightened attention on the use of opioids; INSYS’ ability to secure additional funding as needed; INSYS’ ability to consummate a strategic alternative for its portfolio of opioid-related assets; INSYS’ ability to continue as a going concern; INSYS’ ability to commercialize products successfully; INSYS’ ability to successfully manage its commercial relationships and sales infrastructure; INSYS’ ability to obtain anticipated governmental or regulatory approvals; INSYS’ failure to comply with post-approval regulatory and governmental requirements; the actual sales potential and opportunity of identified markets; and INSYS’ ability to realize the expectations of its pipeline and product candidate plans and timelines. For a further description of these and other risks facing INSYS, please see the risk factors described in the company’s filings with the United States Securities and Exchange Commission, including those factors discussed under the caption “Risk Factors” in the company’s Annual Report on Form 10-K for the year ended December 31, 2018 and subsequent filings. All the information included herein is dated information concerning the company. The company disclaims and does not undertake any obligation to update or revise any forward-looking statements or historical information contained herein.